Skip Navigation

Profile

Edward A. Levine, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

292 Ratings
31 Comments
 

Edward A. Levine, M.D.

Core Director,
Director-At-Large,
Section Head, Surgical Sciences-Oncology
Professor, Surgical Sciences-Oncology

Clinical Interests

Sarcoma, Gastrointestinal Tumors, Esophageal Cancer, Mesothelioma, Peritoneal Carcinomatosis, Esophageal Tumors, Melanoma, Breast Cancer

Contact Information

Returning Patient Appointments: 336-716-4276
Department: 336-716-0545

Email: elevine@wakehealth.edu

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.S., Northern Illinois University, 1981
  • M.D., Finch University of Health Sci/Chicago Med School, 1985
  • Residency, Surgery, Michael Reese Hosp/Med Ctr, 1990
  • Residency, Oncology, U Illinois Hospital, 1992

Board Certifications

  • American Board of Surgery, Surgery

Memberships

  • Nat'L Surgical Adjuvant For Br
  • North Carolina Medical Society
  • Soc Of Surg Of Alimentary Trac
  • Southern Assn For Oncology
  • Southern Medical Association
  • Southern Surgical Assn
  • Southern Surgical Congress
  • Winston-Salem Surgical Society
  • Am Hepato-Pancreato-Biliary
  • Am Coll Of Surgeons
  • Assn Of Academic Surgery
  • Connective Tissue Oncology Soc
  • Alpha Omega Alpha

NPI Number

  • 1275518334
Edward A. Levine, M.D.

Doctor Rating

4.7 out of 5

292 Ratings
31 Comments
 

Edward A. Levine, M.D.

Core Director, Comprehensive Cancer Center
Director-At-Large, Comprehensive Cancer Center
Section Head, Surgical Sciences-Oncology
Professor, Surgical Sciences-Oncology
Office of Women in Medicine and Science

Research Interests

Peritoneal Neoplasms; Hyperthermia, Induced; Chemotherapy, Cancer, Regional Perfusion; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols
More »

Contact Information

Academic: 336-716-0545 | Department: 336-716-0545

Email: elevine@wakehealth.edu

Media Medical Expert »

Recent Publications

A novel T-stage classification system for adrenocortical carcinoma: proposal from the US Adrenocortical Carcinoma Study Group. Poorman CE, Ethun CG, Postlewait LM, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Ann Surg Oncol. 2018;25(2):520-527.

Peritoneal carcinomatosis of urachus origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): an international registry of 36 patients. Mercier F, Passot G, Villeneuve L, Levine EA, Yonemura Y, Goere D, Sugarbaker PH, Marolho C, Bartlett DL, Glehen O.. Ann Surg Oncol. 2018;25(4):1094-1100.

Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International registry. Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(3):667-673.

A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, Bartlett D, Stewart JH.. J Am Coll Surg. 2018;226(4):434-443.

PCI is not predictive of survival after complete CRS/HIPEC in peritoneal dissemination from high-grade appendiceal primaries. Votanopoulos KI, Bartlett D, Moran B, Haroon CM, Russell G, Pingpank JF, Ramalingam L, Kandiah C, Chouliaras K, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(3):674-678.

Clinicopathologic score predicting lymph node metastasis in T1 gastric cancer. Tran TB, Worhunsky DJ, Squires MH, Jin LX, Spolverato G, Votanopoulos KI, Weber SM, Schmidt C, Levine EA, Fields RC, Pawlik TM, Maithel SK, Norton JA, Poultsides GA.. Surgery. 2018;163(4):889-893.

Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA.. Ann Surg Oncol. 2018;():.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma: multi-institutional experience. Liu Y, Yonemura Y, Levine EA, Glehen O, Goere D, Elias D, Morris DL, Sugarbaker PH, Tuech JJ, Cashin P, Spiliotis JD, de Hingh I, Ceelen W, Baumgartner JM, Piso P, Katayama K, Deraco M, Kusamura S, Pocard M, Quenet F, Fushita S.. Ann Surg Oncol. 2018;25(5):1184-1192.

The effect of regional anesthesia on oncologic outcomes after resection of colorectal hepatic metastases. Garland M, Addis D, Russell G, Clark C, Levine E, Howerton R, Votanopoulos K, Dobson S, Shen P.. Am Surg. 2018;84(1):E29-E32.

Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma [abstract]. Ali Y, Sweeney J, Perry KC, Votanopoulos K, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(Suppl 1):S142.

Curative surgical resection of adrenocortical carcinoma: determining long-term outcome based on conditional disease-free probability. Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N,.. Ann Surg. 2017;265(1):197-204.

Minimally invasive resection of adrenocortical carcinoma: a multi-institutional study of 201 patients. Lee CW, Salem AI, Schneider DF, Leverson GE, Tran TB, Poultsides GA, Postlewait LM, Maithel SK, Wang TS, Hatzaras I, Shenoy R, Phay JE, Shirley L, Fields RC, Jin LX, Pawlik TM, Prescott JD, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY,.. J Gastrointest Surg. 2017;21(2):352-362.

Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI.. Ann Surg Oncol. 2017;24(4):890-897.

Phase II randomized trial of negative pressure wound therapy to decrease surgical site infection in patients undergoing laparotomy for gastrointestinal, pancreatic, and peritoneal surface malignancies. Shen P, Blackham A, Lewis S, Clark C, Howerton R, Mogal H, Dodson R, Russell GB, Levine EA.. J Am Coll Surg. 2017;224(4):726-737.

Concordance between patient and provider understanding of intent and nature of treatment [abstract]. Duckworth K, Morrell R, Russell G, Canzona M, Powell B, Levine E, Blackstock W, Streer N, Riffle O, McQuellon R.. Psychooncology. 2017;26(Suppl 1):52.

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED,.. J Hematol Oncol. 2017;10(1):100.

Completion dissection or observation for sentinel-node metastasis in melanoma. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI,.. N Engl J Med. 2017;376(23):2211-2222.

Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Goere D, Passot G, Gelli M, Levine EA, Bartlett DL, Sugarbaker PH, Glehen O.. Int J Hyperthermia. 2017;33(5):520-527.

Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Kim Y, Squires MH, Poultsides GA, Fields RC, Weber SM, Votanopoulos KI, Kooby DA, Worhunsky DJ, Jin LX, Hawkins WG, Acher AW, Cho CS, Saunders N, Levine EA, Schmidt CR, Maithel SK, Pawlik TM.. Surgery. 2017;162(2):285-294.

Interval between cytoreductions as a marker of tumor biology in selecting patients for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Konstantinidis IT, Levine EA, Chouliaras K, Russell G, Shen P, Votanopoulos KI.. J Surg Oncol. 2017;116(6):741-745.

Blood transfusion and survival for resected adrenocortical carcinoma: a study from the United States Adrenocortical Carcinoma Group. Poorman CE, Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Am Surg. 2017;83(7):761-768.

Mutational landscapes of smoking-related cancers in Caucasians and African Americans: precision oncology perspectives at Wake Forest Baptist Comprehensive Cancer Center. Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC,.. Theranostics. 2017;7(11):2914-2923.

Predictors and prognostic implications of perioperative chemotherapy completion in gastric cancer. Karagkounis G, Squires MH III, Melis M, Poultsides GA, Worhunsky D, Jin LX, Fields RC, Spolverato G, Pawlik TM, Votanopoulos KI, Levine EA, Schmidt C, Bloomston M, Cho CS, Weber S, Masi A, Berman R, Pachter HL, Staley CA, Newman E, Maithel SK, Hatzaras I.. J Gastrointest Surg. 2017;21(12):1984-1992.

Outcomes after mastectomy and lumpectomy in octogenarians and nonagenarians with early-stage breast cancer. Merrill AY, Brown DR, Klepin HD, Levine EA, Howard-Mcnatt M.. Am Surg. 2017;83(8):887-894.

Frailty correlates with postoperative mortality and major morbidity after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Konstantinidis IT, Chouliaras K, Levine EA, Lee B, Votanopoulos KI.. Ann Surg Oncol. 2017;24(13):3825-3830.

Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality [reply to letter]. Votanopoulos KI, Shen P, Stewart JH, Levine EA, Russell G.. Ann Surg Oncol. 2017;24(Suppl 3):602.

A comparison of chemotherapy regimens in the treatment of esophageal cancer with chemoradiation therapy with or without surgery [abstract]. Edmunds M, Mctyre E, Soike M, Ayala-Peacock DN, Hughes RT, Zhou Y, Munden RF, Desnoyers R, Levine E, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):E146.

Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Results of an International Multicenter study. Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P, Moran B, Levine EA, Tuech JJ.. Ann Surg. 2016;263(2):369-375.

Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Doud AN, Levine EA, Fino NF, Stewart JH, Shen P, Votanopoulos KI.. Ann Surg Oncol. 2016;23(2):503-510.

Conditional survival after cytoreductive surgery with heated intraperitoneal chemotherapy for low- and high-grade appendiceal primaries. Mogal HD, Levine EA, Russell G, Shen P, Stewart JH, Votanopoulos KI.. Ann Surg Oncol. 2016;23(2):534-538.

To Roux or not to Roux: a comparison between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for gastric cancer. Tran TB, Worhunsky DJ, Squires MH, Jin LX, Spolverato G, Votanopoulos KI, Cho CS, Weber SM, Schmidt C, Levine EA, Bloomston M, Fields RC, Pawlik TM, Maithel SK, Norton JA, Poultsides GA.. Gastric Cancer. 2016;19(3):994-1001.

Is linitis plastica a contraindication for surgical resection: a multi-institution study of the U.S. Gastric Cancer Collaborative. Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI.. Ann Surg Oncol. 2016;23(4):1203-1211.

Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem AI, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N,.. JAMA Surg. 2016;151(4):365-373.

Incidence of perioperative complications following resection of adrenocortical carcinoma and its association with long-term survival. Margonis GA, Amini N, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Moses LE, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. World J Surg. 2016;40(3):706-714.

Routine admission to intensive care unit after cytoreductive surgery and heated intraperitoneal chemotherapy: not always a requirement. Mogal HD, Levine EA, Fino NF, Obiora C, Shen P, Stewart JH, Votanopoulos KI.. Ann Surg Oncol. 2016;23(5):1486-1495.

Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Ann Surg Oncol. 2016;23(1):134-141.

Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM,.. Am J Surg. 2016;211(6):1106-1113.

Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group. Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM,.. J Am Coll Surg. 2016;222(4):480-490.

Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Amini N, Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Ann Surg Oncol. 2016;23(1):126-133.

Significance of intravenous thrombus in the management of adrenocortical carcinoma: prognosis and surgical implications [abstract]. Ahmed S, Tran T, Levine EA, Weber S, Salem AI, Postlewait LM, Maithel SK, Wang T, Hatzaras I, Shenoy R, Phay J, Shirley L, Fields RC, Jin L, Pawlik TM, Prescott J, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM,.. Ann Surg Oncol. 2016;23(Suppl 1):S101.

Multi-institution review of the role of cytoreductive surgery and heated intraperitoneal chemotherapy in metastatic gastric adenocarcinoma in the U.S. [abstract]. Enomoto LM, Choudry MA, Pakrafter S, Magge D, Votanopoulos K, Levine EA, Turaga K, Pameijer C, Wong J.. Ann Surg Oncol. 2016;23(Suppl 1):S22.

Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit? [abstract]. Gerry J, Postlewait LM, Maithel S, Prescott J, Wang T, Glenn JA, Phay J, Keplinger K, Fields RC, Jin L, Weber S, Salem AI, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos K, Levine EA, Hatzaras I, Shenoy R.. Ann Surg Oncol. 2016;23(Suppl 1):S100.

Adjuvant radiation therapy in patients undergoing curative intent resection for adrenocortical carcinoma: a multi-institutional experience [abstract]. Hatzaras I, Rao R, Tran TB, Postlewait LM, Maithel SK, Prescott J, Pawlik TM, Wang T, Phay J, Fields RC, Jin L, Weber S, Salem AI, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos K, Levine EA, Newman E,.. Ann Surg Oncol. 2016;23(Suppl 1):S99.

Stage-specific prognostic effect of race in patients with resectable gastric adenocarcinoma: an 8-institution study of the US Gastric Cancer Collaborative. Wang A, Squires MH III, Melis M, Poultsides GA, Norton JA, Jin LX, Fields RC, Spolverato G, Pawlik TM, Votanopoulos KI, Levine EA, Schmidt C, Bloomston M, Cho CS, Weber S, Berman R, Pachter HL, Newman E, Staley CA, Maithel SK, Hatzaras I.. J Am Coll Surg. 2016;222(4):633-643.

Association of survival, postoperative morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy using quality of life assessments [abstract]. Dodson RM, Mogal H, Russell G, Duckworth KE, Votanopoulos K, Shen P, Levine EA, McQuellon RP.. Ann Surg Oncol. 2016;23(Suppl 1):S35.

Prognostic molecular subtypes of low-grade cancer of the appendix. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD.. J Am Coll Surg. 2016;222(4):493-503.

Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. Mogal H, Chouliaras K, Levine EA, Shen P, Votanopoulos KI.. J Gastrointest Oncol. 2016;7(1):129-142.

Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. Gastric Cancer Collaborative. Randle RW, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI.. J Surg Oncol. 2016;113(7):750-755.

Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA.. J Gastrointest Oncol. 2016;7(1):3-9.

Interaction of postoperative morbidity and receipt of adjuvant therapy on long-term survival after resection for gastric adenocarcinoma: results from the U.S. Gastric Cancer Collaborative. Jin LX, Sanford DE, Squires MH III, Moses LE, Yan Y, Poultsides GA, Votanopoulos KI, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Schmidt C, Worhunsky DJ, Acher AW, Cardona K, Cho CS, Kooby DA, Levine EA, Winslow E, Saunders N,.. Ann Surg Oncol. 2016;23(8):2398-2408.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Surgical Sciences-Oncology

Clinical Interests

Sarcoma, Gastrointestinal Tumors, Esophageal Cancer, Mesothelioma, Peritoneal Carcinomatosis, Esophageal Tumors, Melanoma, Breast Cancer
Edward A. Levine, M.D.

Edward A. Levine, M.D.

Core Director, Comprehensive Cancer Center
Director-At-Large, Comprehensive Cancer Center
Section Head, Surgical Sciences-Oncology
Professor, Surgical Sciences-Oncology
Office of Women in Medicine and Science

Doctor Rating

4.7 out of 5

Edward A. Levine, M.D.292 Ratings
31 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.9
Time CP spent with patient
4.7
Wait time at clinic
3.9



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

4/23/2018

excellent provider!!

4/22/2018

Dr. Levine is a fantastic doctor. The hospital is lucky to have him on staff.

4/19/2018

Dr. Levine is such a wonderful doctor and surgeon. I have not had any cancer cells show up on my scans since he did my surgery. I was a very sick lady - he and his team got me through 7-8 days of recovery.

4/12/2018

the fact the dr. Levine is a specialist pertaining to the rareity of the cancer that I have I extremely reassuring.

4/11/2018

I would highly recommend Dr. Levine.

3/19/2018

very good

2/27/2018

*Dr. Levine is the best!

2/21/2018

I was treated as an individual. I appreciated the physician's willingness to share the story of the sign on the service station.

2/15/2018

Dr. Levine is the best! I am so lucky that they put me with him when my breast mass was discovered. Great bedside manner in addition to being a great surgeon. I'd say that's pretty rare and special!

2/13/2018

I love and trust this hospital and I've lived all over!

2/7/2018

All good.

2/1/2018

Because the provider & staff were so great it was a little easier to overlook the 2+ hour wait, however they need to make some improvements in communication on that.

12/27/2017

Realizing that my doctor is a busy person;I would like to have more time to discuss my concerns.

12/27/2017

I consider Dr Levine to be the best physician I have ever seen. We are highly impressed with him.

12/21/2017

Superb care.

12/19/2017

all good

12/13/2017

Excellent doctor-- and the same for Stephanie, his assistant. She was remarkably patient, knowledgeable, focused on my care. She was especially good when I was in pain.

10/18/2017

9. The best.

10/15/2017

He was in a hurry.

9/27/2017

*Dr. Levine is the oncologist following my case since my 2012 cancer diagnosis.

9/21/2017

good

9/13/2017

I greatly appreciated that Dr. Levine didn't sugarcoat the magnitude of the surgery and the complications, but he also made everything sound very manageable at the same time. I like that he addressed my questions before I had a chance to ask them!! The fact that he wasn't afraid to discuss the complications that he has faced with this surgery and the variety of outcomes in the past, and what factors have influenced those outcomes was very reassuring. I know that there will be a complication of some type, but whether it is big or small, I have confidence that Dr. Levine has encountered it before and has a plan in place for how to manage it. It was helpful to hear not only what the immediate issues/results will be post surgery, but also the mid-range and the long-range ones, too. He truly made me feel as if he was an old, dear friend and was designing my care plan as such, and not as though I was case number "X" this month. His approachability put me at ease.

9/11/2017

Dr. Levine is amazing. He truly cares for his patients!

9/6/2017

Excellent surgeon.

8/23/2017

Dr. and staff were very professional and caring. Answered all questions satisfactorily.

8/7/2017

Dr. Levine is a blessing to us because we had travel along distance to get there and he was awesome.I will never forget his entrance coming into my room. He had made me feel like I had been a patient of his for along time....He was warm hearted, the most beautiful smiling face I had every experience during past doctors visits, friendly, caring, thoughtful, helpful, knowledgeable, and always greets with a hand shake.......I am blessed to have a specialist like him. I will always keep him and his staff in my prayers.

8/1/2017

Dr. Levine is the best and I will recommend him to anyone that has cancer.

7/28/2017

Every experience was good & perfect.

7/11/2017

Excellent!!

6/26/2017

*Dr. Levine is always kind and patient.

6/23/2017

Could not ask to have better care - excellent from start to finish.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.